CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 616 enrolled
Drug / intervention
vilazodonedrug
Likely dose
vilazodone 40 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00644358
NCT00644358Phase 3Completed
CompareCT.gov

A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder

Forest Laboratories·interventional·Posted Mar 26, 2008·Updated Sep 25, 2017

In Brief

A Phase 3 clinical trial evaluating vilazodone for Major Depressive Disorder. Completed, enrolled 616 participants across 38 sites.

Detailed Summary

This open label 52-week clinical trial is designed to assess the safety and tolerability of vilazodone and to analyze genetic markers of response to vilazodone in adult patients diagnosed with MDD. This study will enroll approximately 600 patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 26, 2008
Enrollment StartDec 31, 2007
Primary CompletionMay 31, 2009
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 18.3 years ago

Interventions

vilazodonedrug

titration to 40 milligrams (mg) every day (qd) for 1 year